Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
71
COLL Quote, Financials, Valuation and Earnings
Last price:
$49.56
Seasonality move
:
7.64%
Day range:
$48.50 - $49.59
52-week range:
$23.23 - $49.92
Dividend yield:
0%
P/E ratio:
30.86x
P/S ratio:
2.48x
P/B ratio:
5.70x
Volume:
199K
Avg. volume:
546.7K
1-year change:
70.61%
Market cap:
$1.6B
Revenue:
$631.4M
EPS (TTM):
$1.61
Analysts' Opinion
-
Consensus RatingCollegium Pharmaceutical, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $48.67, Collegium Pharmaceutical, Inc. has an estimated downside of -1.84% from its current price of $49.58.
-
Price Target UpsideAccording to analysts, the highest upside price target is $58.00 representing -100% upside increase from its current price of $49.58.
Fair Value
-
According to the consensus of 4 analysts, Collegium Pharmaceutical, Inc. has -1.84% downside to fair value with a price target of $48.67 per share.
COLL vs. S&P 500
-
Over the past 5 trading days, Collegium Pharmaceutical, Inc. has underperformed the S&P 500 by -0.04% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Collegium Pharmaceutical, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Collegium Pharmaceutical, Inc. has grown year-over-year revenues for 14 quarters straight. In the most recent quarter Collegium Pharmaceutical, Inc. reported revenues of $209.4M.
Earnings Growth
-
Collegium Pharmaceutical, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Collegium Pharmaceutical, Inc. reported earnings per share of $0.84.
Enterprise value:
2.2B
EV / Invested capital:
1.81x
Price / LTM sales:
2.48x
EV / EBIT:
13.52x
EV / Revenue:
2.90x
PEG ratio (5yr expected):
0.26x
EV / Free cash flow:
7.60x
Price / Operating cash flow:
6.49x
Enterprise value / EBITDA:
5.65x
Gross Profit (TTM):
$433.2M
Return On Assets:
3.59%
Net Income Margin (TTM):
7.72%
Return On Equity:
24.26%
Return On Invested Capital:
4.85%
Operating Margin:
30.39%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $546.6M | $599.2M | $757.1M | $159.3M | $209.4M | |
| Gross Profit | $286.1M | $373.7M | $433.2M | $96.8M | $129.2M | |
| Operating Income | $130.4M | $213.4M | $162.5M | $54.7M | $63.6M | |
| EBITDA | $282.2M | $361.5M | $388.7M | $96.5M | $120.1M | |
| Diluted EPS | $0.15 | $2.32 | $1.61 | $0.27 | $0.84 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $363.2M | $405.2M | $537.1M | $443.8M | $613.9M | |
| Total Assets | $741.8M | $1.2B | $1.2B | $1.6B | $1.6B | |
| Current Liabilities | $269M | $414.5M | $464.6M | $459.4M | $452.9M | |
| Total Liabilities | $490.7M | $1B | $998.7M | $1.4B | $1.3B | |
| Total Equity | $251.1M | $197.2M | $178.9M | $234.3M | $274.8M | |
| Total Debt | $270.7M | $730.9M | $717.4M | $991.9M | $934.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $267.7M | $193.7M | $290.9M | -$9M | $78.4M | |
| Cash From Investing | -$46.7M | -$301.1M | -$55.2M | -$249M | -$30.9M | |
| Cash From Financing | -$98.2M | -$87.2M | -$129.7M | $149M | -$14.8M | |
| Free Cash Flow | $266.5M | $192.4M | $289.3M | -$9.2M | $78.3M | |
COLL
Sector
Market Cap
$1.6B
$28.1M
Price % of 52-Week High
99.32%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-2.72%
-1.49%
1-Year Price Total Return
70.61%
-17.13%
Beta (5-Year)
0.613
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$49.01
200-day SMA
Buy
Level
$34.48
Bollinger Bands (100)
Buy
Level
33.93 - 45.17
Chaikin Money Flow
Buy
Level
5M
20-day SMA
Buy
Level
$48.17
Relative Strength Index (RSI14)
Buy
Level
70.34
ADX Line
Buy
Level
30.64
Williams %R
Sell
Level
-9.0186
50-day SMA
Buy
Level
$43.02
MACD (12, 26)
Buy
Level
1.62
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
11.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.9781)
Sell
CA Score
(Annual)
Level (-1.276)
Buy
Beneish M-Score
(Annual)
Level (-2.5284)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (2.1277)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.
Stock Forecast FAQ
In the current month, COLL has received 3 Buy ratings 1 Hold ratings, and 0 Sell ratings. The COLL average analyst price target in the past 3 months is $48.67.
-
Where Will Collegium Pharmaceutical, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Collegium Pharmaceutical, Inc. share price will drop to $48.67 per share over the next 12 months.
-
What Do Analysts Say About Collegium Pharmaceutical, Inc.?
Analysts are divided on their view about Collegium Pharmaceutical, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Collegium Pharmaceutical, Inc. is a Sell and believe this share price will rise from its current level to $44.00.
-
What Is Collegium Pharmaceutical, Inc.'s Price Target?
The price target for Collegium Pharmaceutical, Inc. over the next 1-year time period is forecast to be $48.67 according to 4 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is COLL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Collegium Pharmaceutical, Inc. is a Buy. 3 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of COLL?
You can purchase shares of Collegium Pharmaceutical, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Collegium Pharmaceutical, Inc. shares.
-
What Is The Collegium Pharmaceutical, Inc. Share Price Today?
Collegium Pharmaceutical, Inc. was last trading at $49.56 per share. This represents the most recent stock quote for Collegium Pharmaceutical, Inc.. Yesterday, Collegium Pharmaceutical, Inc. closed at $49.58 per share.
-
How To Buy Collegium Pharmaceutical, Inc. Stock Online?
In order to purchase Collegium Pharmaceutical, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get COLL Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
COLL
Sector
P/E ratio
30.86x
23.89x
PEG ratio
0.26x
-0.01x
P/B ratio
5.70x
1.81x
Price / LTM sales
2.48x
1.59x
Growth Metrics
COLL
Sector
Revenue growth
31.43%
4.62%
Earnings growth
213.22%
11.06%
Revenue (5-year growth)
16.31%
6.5%
Earnings forecast
$1.86
-$0.21
Profitability
COLL
Sector
Profitability FY 2024
$377.3M
$3.6M
Return on invested capital
4.85%
-31.84%
Return on assets
3.59%
-27.96%
Return on equity
24.26%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
5
Balance Sheet
COLL
Sector
Total cash
$305.7M
$26.4M
Short term investments
$92.2M
$25.7M
Total assets
$1.7B
$76.9M
Long term debt
$934.9M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
